KVD001 Injection
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Macular Edema
Conditions
Diabetic Macular Edema
Trial Timeline
Jul 18, 2014 → Jun 4, 2015
NCT ID
NCT02193113About KVD001 Injection
KVD001 Injection is a phase 1 stage product being developed by KalVista Pharmaceuticals for Diabetic Macular Edema. The current trial status is completed. This product is registered under clinical trial identifier NCT02193113. Target conditions include Diabetic Macular Edema.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03466099 | Phase 2 | Completed |
| NCT02193113 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetic Macular Edema
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVT aflibercept + Sham SC + SC CLS-TA | Clearside Biomedical | Phase 2 | 44 |
| CHF6467 active | Comac Medical | Phase 1/2 | 33 |
| Ruboxistaurin mesylate | Eli Lilly | Phase 3 | 77 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 2 | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3857210 + Placebo | Eli Lilly | Phase 2 | 52 |
| UBX1325 | Unity Biotechnology | Phase 2 | 44 |
| Aflibercept + foselutoclax | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 1 | 25 |
| CT-P42 + Eylea | Celltrion | Phase 3 | 77 |
| Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg | Yuhan | Approved | 85 |
| Anplag(Sarpogrelate) + Placebo | Yuhan | Approved | 85 |
| CS-3150 + placebo | Daiichi Sankyo | Phase 2 | 52 |
| DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule | Daiichi Sankyo | Phase 2 | 52 |
| olmesartan medoxomil + Placebo Tablets | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 + placebo | Daiichi Sankyo | Phase 3 | 77 |
| Mirogabalin + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| Beraprost sodium | Astellas Pharma | Pre-clinical | 23 |
| ASP8825 + Placebo | Astellas Pharma | Phase 2 | 52 |